Dermatology
The Pharmacy Times® Dermatology resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
Ceramide-Containing Cleansers and Moisturizing Creams Plus Corticosteroids Have a Synergistic Treatment Effect For Atopic Dermatitis (Eczema)
What can we help you find?
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-06-18_Screen_Shot_2020-06-18_at_11.56.50_AM.png)
Guselkumab is a monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-06-10_AdobeStock_156731686.jpeg)
Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2020-05-04_monday_mystery.jpg)
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/uploadedmedia/images/2019-09-23_Psoriasis_Fotolia_137326803_Subscription_XXL.jpg)
Top news of the day across the health care landscape.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/Eczema_Fotolia_119317413_Subscription_L.jpg)
A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/Psoriasis_Fotolia_137326803_Subscription_XXL.jpg)
Top news of the day from across the health care landscape.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/Psoriasis_Fotolia_137775602_Subscription_XXL.jpg)
Patients Frequently Use Complementary, Alternative Medicines for Psoriasis When Other Therapies Fail
Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/PsoriasisMedicalQuestionnaire_Fotolia_39729576_Subscription_XL.jpg)
The study focused on the comparative risk of infection across 7 systemic biologics.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/shutterstock_310310333.jpg)
Top news of the day from across the health care landscape.
![[[thumbnail_alt_text]]](https://specialtypharmacytimes.s3.amazonaws.com/v1_media/_thumbs/Itch_Fotolia_118800600_Subscription_XXL.jpg)
Top news of the day from across the health care landscape.
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/v1_media/SafeImages/Webdam%20Assets/plaque%20psoriasis.jpg)
A head-to-head trial evaluated quality of life improvements in patients with moderate-to-severe psoriasis treated with secukinumab (Cosentyx) or ustekinumab (Stelara).
![[[thumbnail_alt_text]]](https://pharmacytimes.s3.amazonaws.com/v1_media/SafeImages/Webdam%20Assets/FDA5-644px.jpg)
Top news of the week from Specialty Pharmacy Times.